Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- MSD: Rotavirus Vaccine RotaTeq Oral Solution Approved
January 18, 2012
- Eisai: Insomnia Treatment Lunesta Approved
January 18, 2012
- Astellas: Regnite Approved for RLS
January 18, 2012
- MSD: Cancidas Approved for Treatment of Deep Mycoses
January 18, 2012
- Otsuka: Abilify Obtains Add’l Indication for Manic Symptoms in Bipolar Disorder, OD Tablets as Well
January 18, 2012
- Nobelpharma and Eisai Launch Anticonvulsant Agent Fostoin on Jan. 17
January 17, 2012
- MTPC Licenses Hib Vaccine from Nuron Biotech
January 17, 2012
- 38% of Doctors Will Attend Company-Sponsored Events Only if Transportation, Lodging Costs Are Paid: Survey
January 17, 2012
- 100th Acquisition/License Support Agreement Reached through LSIP Fund
January 17, 2012
- MTPC Issues Apology for Its Researcher’s Arrest on Suspicion of Bodily Harm
January 16, 2012
- President Tamura Says Nichi-Iko to Stop Receiving Marketing Right Transfers of Long-Listed Products
January 16, 2012
- Market for New Oral Anticoagulants Getting Crowded
January 16, 2012
- Sales of DPP-4 Inhibitors on Track to Reach ¥100 Bil. this Fiscal Year
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 16, 2012
- No Clear Road to Distribution Reform; New Drug Premium Hurting Wholesalers’ Business
January 16, 2012
- Research Oriented-companies Shake Up Generics Market with Established Products
January 16, 2012
- Taiyo to Be Core of Teva’s Operations in Japan
January 16, 2012
- Nichi-Iko Will Soon Decide on Independent or Joint PI Trial for Remicade Biosimilar: President Tamura
January 16, 2012
- Otsuka to Focus on CNS Field, Ending Collaboration in Immunology, Inflammation with UCB
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…